Airway Therapeutics clôture un tour de table de 50 millions de dollars pour faire avancer le développement en phase avancée du zelpultide alfa

zelpultide alfaPositive

AI Analysis

Summary

Airway Therapeutics closed a $50 million Series E-2 funding round with approximately 94% participation from existing investors to advance the Phase 2b/3 clinical trial of zelpultide alfa for bronchopulmonary dysplasia prevention.

Clinical Trial Data

Phase

2b/3

Importance:6/10

Sentiment:

0.60

fundingSeries E-2Phase 2b/3zelpultide alfabronchopulmonary dysplasia

Read the original article

Published by PR Newswire Biotech on August 25, 2026 1:00 PM

Read Original